ArticleAmerican journal of epidemiology2020
Does Combining Severe and Mild Cases of COVID-19 Produce Low Fatality Rates After Treatment With Hydroxychloroquine and Azithromycin?
Article in American journal of epidemiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A comment-driven evidence appraisal approach to promoting research findings into practice when only uncertain evidence is available.Health research policy and systems · 2023Article
- The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19.Frontiers in pharmacology · 2021Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of the Journal, Dr. Risch (Am J Epidemiol. 2020;189(11):1218-1226) posits that the use of a combination of hydroxychloroquine and azithromycin as an outpatient treatment for high-risk patients with coronavirus 19 should be increased as a way to help curtail the ongoing pandemic. However, a calculation error occurred in the original article, and new data about the studies cited have come to light. Peculiarities in the methods of data collection and reporting in those original sources must be considered when evaluating the evidence for or against hydroxychloroquine and azithromycin bitherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.